within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CR03_TicarcillinAndBetaLactamaseInhibitor;
model TicarcillinAndBetaLactamaseInhibitor 
   extends Pharmacolibrary.Drugs.ATC.J.J01CR03;

  annotation(Documentation(
    info ="<html><body><p>Ticarcillin is a broad-spectrum penicillin antibiotic that is primarily used in combination with a beta-lactamase inhibitor (typically clavulanic acid) to extend its activity against beta-lactamase-producing organisms. The combination is indicated for the treatment of various serious bacterial infections, including lower respiratory tract, urinary tract, intra-abdominal, and gynecological infections. In many countries, this formulation has been discontinued or is used less commonly today due to the development of newer agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for ticarcillin in combination with clavulanic acid in healthy adults, intravenous administration. Data are estimated from historical single-dose studies and reviews, as no recent publications with detailed compartmental PK parameters are available.</p><h4>References</h4><ol><li><p>Reed, MD (1998). Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: focus on ticarcillin/clavulanic acid. <i>The Annals of pharmacotherapy</i> 32(1) S17–S21. DOI:<a href=&quot;https://doi.org/10.1177/106002809803200105&quot;>10.1177/106002809803200105</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9475835/&quot;>https://pubmed.ncbi.nlm.nih.gov/9475835</a></p></li><li><p>Hart, SM, &amp; Bailey, EM (1996). A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations. <i>The Annals of pharmacotherapy</i> 30(10) 1130–1140. DOI:<a href=&quot;https://doi.org/10.1177/106002809603001013&quot;>10.1177/106002809603001013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8893121/&quot;>https://pubmed.ncbi.nlm.nih.gov/8893121</a></p></li><li><p>Wilson, WD, et al., &amp; Pryor, P (1991). Pharmacokinetics and bioavailability of ticarcillin and clavulanate in foals after intravenous and intramuscular administration. <i>Journal of veterinary pharmacology and therapeutics</i> 14(1) 78–89. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2885.1991.tb00807.x&quot;>10.1111/j.1365-2885.1991.tb00807.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2038098/&quot;>https://pubmed.ncbi.nlm.nih.gov/2038098</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end TicarcillinAndBetaLactamaseInhibitor;
